- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07947615
Anti-Adalimumab Antibodies in Children With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis (ADA AIG-U)
Anti-Adalimumab Antibodies in a Prospective Cohort of Patients With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis: Incidence, Predictive Factors, and Clinical Correlations
This prospective, single-center observational cohort study aims to investigate the development of anti-Adalimumab antibodies in pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis initiating Adalimumab treatment.
The study will assess the frequency and timing of antibody development, identify potential predictive factors, including concomitant methotrexate treatment, and explore associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 patients will be enrolled and followed for 24 months. Clinical data and additional blood samples will be collected at baseline and at 3, 6, 12, 18, and 24 months during routine clinical visits.
Anti-Adalimumab antibodies and serum drug concentrations will be measured using surface plasmon resonance (SPR) technology. Treatment decisions will remain entirely based on routine clinical practice.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Adalimumab is widely used in the treatment of juvenile idiopathic arthritis (JIA) and chronic non-infectious uveitis. Despite its established efficacy, some patients experience inadequate clinical response, secondary loss of efficacy, or disease flares during treatment. The development of anti-Adalimumab antibodies (AAA) may contribute to reduced serum drug concentrations and impaired therapeutic response. However, evidence regarding the incidence, timing, and clinical significance of AAA in paediatric patients remains limited and heterogeneous.
This prospective, single-centre, observational cohort study aims to investigate the development and kinetics of AAA in paediatric patients with JIA and/or chronic non-infectious uveitis initiating Adalimumab treatment. The study will also explore potential predictive factors for AAA development, including concomitant methotrexate therapy, and evaluate associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 Adalimumab-naïve patients will be consecutively enrolled at AOU Meyer IRCCS, Florence, Italy. All participants will receive Adalimumab according to routine clinical practice, independently of study participation. No investigational treatment or study-related therapeutic intervention is planned.
Each participant will be followed for 24 months, with assessments at baseline and at 3, 6, 12, 18, and 24 months. Clinical and laboratory data will be collected during routine follow-up visits, including demographic characteristics, disease subtype and duration, concomitant treatments, disease activity measures, inflammatory markers, disease flares, and treatment modifications.
At each scheduled assessment, an additional 5 mL peripheral blood sample will be collected during routine blood sampling. Serum samples will be analysed at the PeptLab laboratory of the University of Florence using surface plasmon resonance (SPR) technology to determine AAA positivity and levels, as well as serum Adalimumab concentrations. AAA positivity will be defined according to a predefined threshold of 15 Response Units (RU).
The primary outcomes are the proportion of patients developing AAA during follow-up and the time from Adalimumab initiation to the first detection of AAA. Secondary outcomes include the identification of clinical and treatment-related factors associated with AAA development, changes in disease activity and functional assessment scores (JADAS-10 and CHAQ), inflammatory markers, occurrence and number of disease flares, and persistence of AAA positivity.
Statistical analyses will include descriptive and exploratory multivariable methods, longitudinal models for repeated measurements, and time-to-event analyses accounting for interval censoring when appropriate. Particular attention will be given to the potential association between concomitant methotrexate treatment and AAA development.
The overall study duration is expected to be 72 months, including 36 months of recruitment, individual follow-up, and final data analysis and reporting.
The study aims to improve understanding of Adalimumab immunogenicity in paediatric JIA and chronic non-infectious uveitis and to explore the potential clinical value of immunopharmacological monitoring in identifying patients at risk of secondary treatment failure or disease relapse.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: LUCIA PAOLINI
- Numéro de téléphone: 390555662499
- E-mail: lucia.paolini@meyer.it
Lieux d'étude
-
-
-
Florence, Italie
- Recrutement
- Aou Meyer IRCSS
-
Contact:
- LUCIA PAOLINI
- Numéro de téléphone: +390555662545
- E-mail: lucia.paolini@meyer.it
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis followed at the Pediatric Rheumatology Unit of AOU Meyer IRCCS, Florence, Italy, for whom initiation of Adalimumab treatment is clinically indicated.
Eligible patients must be Adalimumab-naïve and will be consecutively enrolled during routine outpatient or day-hospital visits. Treatment decisions will be made independently of study participation, according to standard clinical practice.
La description
Inclusion Criteria:
Age at diagnosis between 2 and 16 years.
Diagnosis of juvenile idiopathic arthritis (JIA) according to the International League of Associations for Rheumatology (ILAR) criteria, established on or after January 1, 2015, and/or diagnosis of chronic non-infectious uveitis according to the Standardization of Uveitis Nomenclature (SUN) Working Group criteria, established on or after January 1, 2015.
Clinical indication to initiate Adalimumab treatment in patients with no previous exposure to Adalimumab (Adalimumab-naïve), as determined by the treating physician.
Written informed consent from parents or legal guardians and assent from minors aged 7 years or older, where applicable.
Exclusion Criteria:
Age 18 years or older at enrollment.
Diagnoses other than juvenile idiopathic arthritis or chronic non-infectious uveitis.
Contraindications to Adalimumab, including tuberculosis exposure, history of multiple sclerosis or other demyelinating central nervous system disorders, or history of malignancy.
Previous exposure to Adalimumab before study enrollment.
Body weight below 12 kg.
Age below 24 months at enrollment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Adalimumab-treated patients with JIA and/or chronic non-infectious uveitis
Pediatric patients diagnosed with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis who are initiating Adalimumab treatment according to routine clinical practice and have not previously received Adalimumab. Patients will be prospectively followed for 24 months, with clinical assessments and blood sample collection at baseline and at 3, 6, 12, 18, and 24 months to evaluate the development of anti-Adalimumab antibodies, serum drug concentrations, and clinical outcomes. |
Anti-Adalimumab Antibody and Serum Drug Level Assessment by SPR |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of Patients Developing Anti-Adalimumab Antibodies
Délai: Baseline and Months 3, 6, 12, 18, and 24
|
Proportion of patients with detectable anti-Adalimumab antibodies (AAA) during the 24-month follow-up, assessed using surface plasmon resonance (SPR). Antibody positivity will be defined using a predefined cut-off of 15 Response Units (RU). |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Time to Development of Anti-Adalimumab Antibodies
Délai: From baseline to Month 24.
|
Time from initiation of Adalimumab treatment to the first detection of anti-Adalimumab antibodies, assessed at scheduled follow-up visits. The analysis will account for interval censoring between the last negative and first positive antibody determinations. |
From baseline to Month 24.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Factors Associated With Anti-Adalimumab Antibody Development
Délai: Baseline to Month 24
|
Assessment of the association between anti-Adalimumab antibody (AAA) development and demographic, clinical, and laboratory factors, including sex, age, JIA subtype according to ILAR classification, disease duration, baseline inflammatory markers, and serum Adalimumab concentrations. |
Baseline to Month 24
|
|
Association Between Concomitant Methotrexate Treatment and AAA Development
Délai: Baseline to Month 24
|
Assessment of the proportion of patients developing anti-Adalimumab antibodies according to concomitant methotrexate treatment (yes/no), including the time to antibody development where appropriate. |
Baseline to Month 24
|
|
Change in Juvenile Arthritis Disease Activity Score (JADAS-10)
Délai: Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in disease activity using the Juvenile Arthritis Disease Activity Score (JADAS-10) during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Change in Childhood Health Assessment Questionnaire (CHAQ) Score
Délai: Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in functional disability using the Childhood Health Assessment Questionnaire (CHAQ) during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Change in Inflammatory Markers (ESR and CRP)
Délai: Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Proportion of Patients Experiencing at Least One Disease Flare
Délai: Baseline to Month 24
|
Proportion of patients experiencing at least one articular or ocular disease flare during the 24-month follow-up, according to the definitions established in the study protocol. |
Baseline to Month 24
|
|
Number of Disease Flares per Patient
Délai: Baseline to Month 24
|
Total number of articular and/or ocular disease flares recorded for each patient during the 24-month follow-up period. |
Baseline to Month 24
|
|
Persistence of Anti-Adalimumab Antibody Positivity
Délai: Baseline to Month 24
|
Proportion of anti-Adalimumab antibody-positive patients showing persistent antibody positivity, defined as two positive determinations performed at least six months apart. |
Baseline to Month 24
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ADA AIG-U
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .